Participant flow

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Laboratory Biomarker Analysis: Correlative studies Rituximab: Given IV

   id

   FG000

   title

   Treatment (Ixazomib Citrate, Rituximab)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

   3. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      Follicular Lymphoma (FL)

   4. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      Marginal Zone Lymphoma (MZL)

   5. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      Mantle Cell Lymphoma (MCL)

   6. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL)

   7. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      COMPLETED

   8. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice